Comparison of Visual Fields: Humphrey Field Analyzer (HFA) SITA Strategy, SCOPE (GATE Strategy) and Humphrey MATRIX Perimeter

• Conditions: Glaucoma

• Registration Number: NCT01068938
• Lead Sponsor: University Hospital Tuebingen

Brief Summary

The purpose of this study is to compare three perimetric techniques regarding progression of the visual field.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-11
• Study First Submitted: 2010-02-16
• Study First Submitted QC: 2010-02-16
• Study First Posted: 2010-02-17
• Primary Completion: 2013-12
• Status Verified: 2016-12
• Study Completion: 2016-12
• Last Update Submitted: 2016-12-19
• Last Update Posted: 2016-12-20

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• max. ± 8 dpt sph, max. ± 3 dpt cyl
• distant visual acuity > 10/20
• isocoria, pupil diameter > 3 mm
• at least one risk of progression: optic disc (splinter) hemorrhage / cup to disc ratio (CDR) > 0.7 / inter-eye asymmetry of CDR >0.2 / notching of the optic disc /retinal nerve fibre layer (RNFL) defects / intraocular pressure( IOP) >22 mmHg / central corneal thickness < 520 µm / advanced visual field defect stage Aulhorn III / elder than 70 years

Exclusion Criteria

• pregnancy, nursing
• diabetic retinopathy
• asthma
• HIV+ or AIDS
• history of epilepsy or significant psychiatric disease
• medications known to effect visual field sensitivity
• infections (e.g. keratitis, conjunctivitis, uveitis)
• severe dry eyes
• miotic drug
• amblyopia
• squint
• nystagmus
• albinism
• any ocular pathology, in either eye, that may interfere with the ability to obtain visual fields,disc imaging or accurate IOP readings
• keratoconus
• intraocular surgery (except for uncomplicated cataract surgery) performed < 3 month prior to screening
• history or signs of any visual pathway affection other than glaucoma
• allergies with regard to topic glaucoma medication
• history or presence of macular disease and / or macular edema
• ocular trauma
• medications known to affect visual field sensitivity

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
glaucoma progression	6 month

Trial Locations

Locations (1)

Centre for Ophthalmology, Institute for Ophthalmic Research; 🇩🇪 Tuebingen, Germany